Abstracts Archive - Page 1098 of 2425 - ACR Meeting Abstracts

Abstract Number: 1401 • 2018 ACR/ARHP Annual Meeting
Is There a Specific Effect of Jak-Inhibitors on Pain and Fatigue in Rheumatoid Arthritis?
Itsaso Odriozola¹, Claire-Sophie Coste¹, Thomas Barnetche^2,3, Christophe Richez^4,5, Bernard Bannwarth¹ and Thierry Schaeverbeke⁶, ¹Rheumatology, CHU de Bordeaux, Bordeaux, France, ²FHU ACRONIM, Pellegrin Hospital, Bordeaux University, Bordeaux, France, ³Rheumatology, Centre hospitalier universitaire de Bordeaux - Service de Rhumatologie, Bordeaux, France, ⁴UMR CNRS 5164 - Immunoconcept, Bordeaux, France, ⁵Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ⁶Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France
Background/Purpose: Pain and fatigue are common symptoms for patients with rheumatoid arthritis (RA).JAK inhibitors (JAKi) already proved similar efficacy on disease activity as bDMARD (anti-TNF,…
Abstract Number: 1402 • 2018 ACR/ARHP Annual Meeting
The Relationship of Pain, Fatigue and Emotional Distress with Quality of Life in Juvenile Myositis
Kyle J. Fahey¹, Elizabeth L. Gray², Rowland W. Chang³, David Cella⁴, Lauren M. Pachman⁵ and Kaveh Ardalan⁶, ¹Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Preventive Medicine, Medicine, and Physical Medicine & Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Departments of Medical Social Sciences, Neurology, Pediatrics, Preventive Medicine, and Psychiatry and Behavioral Sciences,, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁶Departments of Pediatrics and Medical Social Sciences, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile Myositis (JM) is an autoimmune disease that negatively impacts quality of life (QoL) outcomes via muscle weakness and vasculopathic rashes. The relative contribution…
Abstract Number: 1403 • 2018 ACR/ARHP Annual Meeting
Estimates of Minimally Important Differences and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short-Forms Among Individuals with SLE
Patricia Katz^1,2, Evo Alemao³, Jayanti Mukherjee³ and Kaleb Michaud^2,4, ¹Forward/National Data Bank for Rheumatic Diseases, Wichita, KS, ²University of California San Francisco, San Francisco, CA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: As the NIH PROMIS (Patient-Reported Outcomes Measurement Information System) measures are used more widely, information is needed to enhance interpretation. Minimally important differences (MIDs;…
Abstract Number: 1404 • 2018 ACR/ARHP Annual Meeting
Responsiveness of Promis (Patient Reported Outcomes Measurement Information System) Measures in a Multi-Racial, Multi-Ethnic Systemic Lupus Erythematosus (SLE) Cohort
Patricia Katz¹, Stephanie Rush², Jinoos Yazdany³, Laura Trupin¹, Louise Murphy⁴, Cristina Lanata¹, Lindsey A. Criswell¹ and Maria Dall'Era³, ¹University of California San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Recent studies have demonstrated the reliability and validity of the NIH PROMIS (Patient-Reported Outcomes Measurement Information System) measures in SLE. Analyses of their responsiveness…
Abstract Number: 1405 • 2018 ACR/ARHP Annual Meeting
Assessment of the Psychometric Properties of Patient-Reported Outcomes of Depression in SLE
Andrew Kwan¹, Sherief Marzouk², Helia Ghanean², Michelle Vitti³, Kishwar Ali³, Dennisse Bonilla³, Nicole Anderson³, Jiandong Su³ and Zahi Touma³, ¹Faculty of Medicine, Queen's University, Kingston, ON, Canada, ²Psychiatry, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mood disorders, including depression, are amongst the most common manifestations of neuro-psychiatric SLE. Currently, the screening and diagnosis for depression in ambulatory settings are…
Abstract Number: 1406 • 2018 ACR/ARHP Annual Meeting
Longitudinal Construct Validity of the Psaid Individual Items: Can We Eliminate Other Questionnaires If Using the Psaid?
Jessica Walsh¹, Jose U. Scher², Soumya M. Reddy³, M. Elaine Husni⁴ and Alexis Ogdie⁵, ¹University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ²New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ⁵Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Psoriatic Arthritis Impact of Disease (PsAID) questionnaire is a patient reported measure of disease impact. The 12-item questionnaire has many advantages including demonstrated…
Abstract Number: 1407 • 2018 ACR/ARHP Annual Meeting
Differences in the Measurement Properties of the Patient-Reported Outcomes Measurement Information System Physical Function Short-Form 10a Among Racial/Ethnic Minorities with Rheumatoid Arthritis
Zara Izadi¹, Patricia Katz², Gabriela Schmajuk³, Julie Gandrup⁴, Jing Li⁵, Milena Gianfrancesco⁶ and Jinoos Yazdany⁷, ¹Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ⁴Rheumatology, Odense University Hospital, Odense, Denmark, ⁵Medicine, UC San Francisco, San Francisco, CA, ⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Most studies evaluating patient-reported outcomes such as the PROMIS Physical Function Short Form 10a (PF10a) in rheumatoid arthritis (RA) have been performed in white…
Abstract Number: 1408 • 2018 ACR/ARHP Annual Meeting
Using Patient Reported Outcomes at Point of Care in Immune Mediated Diseases: Minimal Clinically Important Differences
M. Elaine Husni¹, Chad Deal², Leonard H. Calabrese³, Greg Strnad⁴, James Bena⁵ and Abby Abelson⁶, ¹Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Shaker Heights, OH, ³Rheumatology, Cleveland Clinic, Cleveland, OH, ⁴Cleveland Clinic, Cleveland, OH, ⁵Quantitative Health Science, QHS Cleveland Clinic, Cleveland, OH, ⁶Department of Rheumatologic & Immunologic Disease, Cleveland Clinic, Cleveland, OH
Background/Purpose: Patient reported measures of global health and disease activity are increasingly used in routine care; however, detecting meaningful change in clinical status (responsiveness) is difficult…
Abstract Number: 1409 • 2018 ACR/ARHP Annual Meeting
Empowerment in Hispanic Rheumatoid Arthritis Patients: A Validation Study
Emmanuel Ruiz-Medrano¹, Irazú Contreras-Yáñez², Luz del Carmen Hernández³ and Virginia Pascual-Ramos⁴, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³UCB Pharmaceutical, Mexico City, Mexico, ⁴Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The World Health Organization describes empowerment in health promotion work as a process in which the person receives more control over decisions and actions…
Abstract Number: 1410 • 2018 ACR/ARHP Annual Meeting
Assessment of Work Outcomes with Truncation from Job Loss in an Arthritis Randomized Clinical Trial
Michael P. LaValley¹, Carrie Brown^1,2, David T. Felson^3,4 and Julie Keysor⁵, ¹Biostatistics, Boston University School of Public Health, Boston, MA, ²The Emmes Corporation, Rockville, MD, ³ARC Epidemiology Unit, University of Manchester, Manchester, MA, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Physical Therapy, MGH Institute of Health Professions, Boston, MA
Background/Purpose: Methods for causal analysis in randomized clinical trials (RCT) where functional outcomes may be truncated by death of participants have been developed but are…
Abstract Number: 1411 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Different Doses of Canakinumab (<2, 2–<4, and 4–<8 mg/kg) in Patients Aged <4–≥65 Years: Results from the β-Confident Registry
Jasmin B. Kuemmerle-Deschner¹, Ulrich A. Walker², Hugh H. Tilson³, Philip N. Hawkins⁴, Tom van der Poll⁵, Kristina Franke⁶, Antonio Speziale⁷, Eleni Vritzali⁷ and Hal M. Hoffman⁸, ¹Pediatrics, University Hospital Tübingen, Tübingen, Germany, ²Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ³University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, ⁴University College London Medical School, London, United Kingdom, ⁵Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁶IQVIA, Durham, NC, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸University of California, San Diego, San Diego, CA
Background/Purpose: Canakinumab (CAN), a human anti-interleukin-1 monoclonal antibody, has shown to be efficacious and safe in the treatment of all phenotypes of cryopyrin-associated periodic syndrome…
Abstract Number: 1412 • 2018 ACR/ARHP Annual Meeting
A Systematic Literature Review of Efficacy and Safety of Current Therapies for the Treatment of Hyperimmunoglobulinemia D Syndrome and TNF Receptor-Associated Periodic Syndrome
Jasmin B. Kuemmerle-Deschner¹, Raju Gautam², Aneesh Thomas George², Syed Raza², Kathleen Graham Lomax³ and Peter Hur³, ¹Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital, Tuebingen, Germany, Tuebingen, Germany, ²Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India, ³Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ
Background/Purpose: Hyperimmunoglobulinemia D syndrome (HIDS), also known as mevalonate kinase deficiency (MKD), and TNF receptor-associated periodic syndrome (TRAPS) are rare auto-inflammatory diseases grouped as periodic…
Abstract Number: 1413 • 2018 ACR/ARHP Annual Meeting
Safety of Tocilizumab in Patients Aged <2 Years with Active Systemic Juvenile Idiopathic Arthritis Treated for One Year
Sunethra Wimalasundera¹, Inmaculada Calvo², Rubén J. Cuttica³, Hans-Iko Huppertz⁴, Rik Joos⁵, Diana Milojevic⁶, Margalit Rosenkranz⁷, Kenneth Schikler⁸, Tamás Constantin⁹, Wendy Douglass¹, Chris Wells¹, Yukiko Kimura¹⁰ and Carine Wouters¹¹, ¹Roche Products Ltd., Welwyn Garden City, United Kingdom, ²Hospital Universitario La Fe, Valencia, Spain, ³Hospital General de Niños Pedro de Elizalde, Buenes Aires, Argentina, ⁴Professor Hess Children's Hospital, Bremen, Germany, ⁵ZNA, Antwerp, and UZ, Gent, Belgium, ⁶Tufts Medical Center, Boston, MA, ⁷Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁸University of Louisville Medical School, Louisville, KY, ⁹Semmelweis University, Budapest, Hungary, ¹⁰Hackensack University Medical Center, Hackensack, NJ, ¹¹University Hospital Gasthuisberg, Leuven, Belgium
Background/Purpose: The US Food and Drug Administration approved intravenous (IV) tocilizumab (TCZ) for patients (pts) ≥2 years of age with systemic JIA (sJIA) in 2011…
Abstract Number: 1414 • 2018 ACR/ARHP Annual Meeting
Pharmacovigilance of Biologics for Systemic Juvenile Idiopathic Arthritis Patients By the German Biologics Registry
Gerd Horneff¹, Gerd Ganser², Toni Hospach³, Ivan Foeldvari⁴, Michael Borte⁵, Frank Weller-Heinemann⁶, Kirsten Minden⁷ and Ariane Klein⁸, ¹Asklepios Kinderklinik St. Augustin GmbH, Sankt Augustin, Germany, ²Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, ³Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, ⁴Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ⁵St Georg Hospital, Leipzig, Germany, ⁶PRINTO, Genoa, Italy, ⁷Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁸Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Long-term surveillance of biologic drugs is particularly important in pediatric patients(pts). Since 2001, the German Biologics JIA Registry (BIKER) is allowing to follow up…
Abstract Number: 1415 • 2018 ACR/ARHP Annual Meeting
Emapalumab, an Anti-Interferon Gamma Monoclonal Antibody in Two Patients with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)
Claudia Bracaglia¹, Giusi Prencipe¹, Antonella Insalaco¹, Ivan Caiello², Giulia Marucci¹, Raffaele Pecoraro³, Manuela Pardeo¹, Pavla Dolezalova⁴, Sarka Fingerhutova⁴, Maria Ballabio⁵, Cristina de Min⁵ and Fabrizio De Benedetti⁶, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³Pediatric Department, La Sapienza University of Rome, Rome, Italy, ⁴Paediatric Rheumatology Unit, General University Hospital in Prague and 1st Faculty of Medicine, Charles University, General University Hospital in Prague and 1st Faculty of Medicine, Prague, Czech Republic, ⁵NovImmune S.A., Geneva, Switzerland, ⁶IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Interferon gamma (IFNγ) plays a pathogenic role in primary and secondary HLH. An ongoing phase 2/3 trial with emapalumab in primary HLH provides encouraging…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].